Avalo Therapeutics Inc, a clinical-stage biotech firm based in Rockville, Maryland with 20 employees, focuses on developing therapies targeting the LIGHT-signaling network for immune dysregulation. Their key products include AVTX-002 for various disorders and AVTX-008, a BTLA agonist fusion protein, with the company going public in 2015.
AVTX filed a patent for "methods and treatment involving excess free light" on Mon, June 5, 2023. The patent was officially published on Thu, January 4, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
